Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

intervacc ab - recombinant streptococcus equi protein cce, recombinant streptococcus equi protein eq85, recombinant streptococcus equi protein idee - imunologická data pro koňovité - koně - for the active immunisation to reduce clinical signs and the number of abscesses in acute stage of infection with s. equi.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

janssen-cilag international n.v. - teclistamab - mnohočetný myelom - antineoplastická činidla - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

accord healthcare polska sp. z o.o., varšava array - 14175 trihydrÁt natrium-alendronÁtu; 15455 prÁŠkovÝ cholekalciferol - tableta - 70mg/2800iu - kyselina alendronovÁ a cholekalciferol

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

accord healthcare polska sp. z o.o., varšava array - 14175 trihydrÁt natrium-alendronÁtu; 15455 prÁŠkovÝ cholekalciferol - tableta - 70mg/5600iu - kyselina alendronovÁ a cholekalciferol

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

instituto grifols, s.a., barcelona array - 3531 lidskÝ koagulaČnÍ faktor viii; 17457 lidskÝ von willebrandŮv faktor - prášek a rozpouštědlo pro injekční roztok - 100iu/ml - koagulaČnÍ faktor viii a von willebrandŮv faktor v kombinaci

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

instituto grifols, s.a., barcelona array - 3531 lidskÝ koagulaČnÍ faktor viii; 17457 lidskÝ von willebrandŮv faktor - prášek a rozpouštědlo pro injekční roztok - 25iu/ml - koagulaČnÍ faktor viii a von willebrandŮv faktor v kombinaci

Τσεχική Δημοκρατία - Τσεχικά - SUKL (Státní ústav pro kontrolu léčiv)

instituto grifols, s.a., barcelona array - 3531 lidskÝ koagulaČnÍ faktor viii; 17457 lidskÝ von willebrandŮv faktor - prášek a rozpouštědlo pro injekční roztok - 50iu/ml - koagulaČnÍ faktor viii a von willebrandŮv faktor v kombinaci

Ευρωπαϊκή Ένωση - Τσεχικά - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - mnohočetný myelom - antineoplastická činidla - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.